Pfizer's berobenatide weight‑loss drug draws market attention

Pfizer is advancing berobenatide, an investigational weight‑loss therapy that achieved about a 16% reduction in body weight over 32 weeks in a phase 2b trial. The drug is positioned to compete with established anti‑obesity medicines such as Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy, and could benefit from a once‑monthly dosing schedule.

Following the release of earnings that beat expectations, Pfizer’s share price rose roughly 1.9% in mid‑day trading. The company reported adjusted EPS of $0.77 versus $0.68 consensus, revenue of $15.03 billion, and raised its 2026 revenue outlook while expanding its cost‑savings target. Strong demand for the blood‑thinner Eliquis and progress on pipeline projects, including a variant‑adapted COVID‑19 booster, also supported the stock move.